المؤلفون: Brian T. Hopkins (2723545), Eris Bame (7038266), Bekim Bajrami (230244), Cheryl Black (11647791), Tonika Bohnert (2700703), Carrie Boiselle (11647794), Doug Burdette (8379867), Jeremy C. Burns (9903441), Luisette Delva (11647797), Douglas Donaldson (6387041), Richard Grater (11647800), Chungang Gu (1638805), Marc Hoemberger (11647803), Josh Johnson (831725), Sudarshan Kapadnis (3829360), Kris King (11647806), Mukesh Lulla (11647809), Bin Ma (219839), Isaac Marx (11647812), Tom Magee (11647815), Robert Meissner (384997), Claire M. Metrick (9214871), Michael Mingueneau (4182721), Paramasivam Murugan (8042474), Kevin L. Otipoby (9214862), Evelyne Polack (9025907), Urjana Poreci (9214874), Robin Prince (11647818), Allie M. Roach (11647821), Chris Rowbottom (11647824), Joseph C. Santoro (8042477), Patricia Schroeder (647768), Hao Tang (44155), Eric Tien (424500), Fengmei Zhang (836324), Joseph Lyssikatos (1577434)

مصطلحات موضوعية: Biophysics, Biochemistry, Medicine, Genetics, Neuroscience, Pharmacology, Biotechnology, Immunology, Cancer, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, treating autoimmune diseases, tolerability profile suitable, important phosphorylation site, high potency molecule, central nervous system, axonal injury leading, superior safety profiles, inflammation processes leading, selective btk inhibitor, highly selective, reversible inhibitor, unmet need, sequester tyr, primary driver, preclinical characterization, like properties, inactive conformation, good drug, excellent affinity

Relation: https://figshare.com/articles/journal_contribution/Discovery_and_Preclinical_Characterization_of_BIIB091_a_Reversible_Selective_BTK_Inhibitor_for_the_Treatment_of_Multiple_Sclerosis/16930248

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c00926.s001

المؤلفون: Brian T. Hopkins (2723545), Eris Bame (7038266), Bekim Bajrami (230244), Cheryl Black (11647791), Tonika Bohnert (2700703), Carrie Boiselle (11647794), Doug Burdette (8379867), Jeremy C. Burns (9903441), Luisette Delva (11647797), Douglas Donaldson (6387041), Richard Grater (11647800), Chungang Gu (1638805), Marc Hoemberger (11647803), Josh Johnson (831725), Sudarshan Kapadnis (3829360), Kris King (11647806), Mukesh Lulla (11647809), Bin Ma (219839), Isaac Marx (11647812), Tom Magee (11647815), Robert Meissner (384997), Claire M. Metrick (9214871), Michael Mingueneau (4182721), Paramasivam Murugan (8042474), Kevin L. Otipoby (9214862), Evelyne Polack (9025907), Urjana Poreci (9214874), Robin Prince (11647818), Allie M. Roach (11647821), Chris Rowbottom (11647824), Joseph C. Santoro (8042477), Patricia Schroeder (647768), Hao Tang (44155), Eric Tien (424500), Fengmei Zhang (836324), Joseph Lyssikatos (1577434)

مصطلحات موضوعية: Biophysics, Biochemistry, Medicine, Genetics, Neuroscience, Pharmacology, Biotechnology, Immunology, Cancer, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, treating autoimmune diseases, tolerability profile suitable, important phosphorylation site, high potency molecule, central nervous system, axonal injury leading, superior safety profiles, inflammation processes leading, selective btk inhibitor, highly selective, reversible inhibitor, unmet need, sequester tyr, primary driver, preclinical characterization, like properties, inactive conformation, good drug, excellent affinity

Relation: https://figshare.com/articles/dataset/Discovery_and_Preclinical_Characterization_of_BIIB091_a_Reversible_Selective_BTK_Inhibitor_for_the_Treatment_of_Multiple_Sclerosis/16930251

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c00926.s002